Aclarion, Inc. ACON 深 滬
已收盤 08-08 16:00:00 美东时间
7.166
-0.144
-1.97%
華盛通- 最 高7.65
- 今 開7.305
- 成交量 1.48万股
- 最 低 7.166
- 昨 收 7.31
- 總市值 417.35万
- 52周最高 3499.5105
- 市盈率 靜 --
- 換手率 2.54%
- 52周最低 6.20
- 委 比 -80.13%
- 總股本 58.24万
- 歷史最高 586116.00
- 量 比 0.92
- 振 幅 6.62%
- 歷史最低 7.166
- 每 手 1
- 風險率 822.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Auddia Plans Merger With AI-Focused Thramann Holdings, Will Rebrand as New Public Tech Powerhouse
Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), today announced that in follow up to the leadership and strategic changes announced last month the Company's Board, acting upon the recommendation of
08-05 18:10
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
Aclarion, Inc. announced a 132% year-over-year increase in Nociscan scan volumes from Q2 2024 to Q2 2025, driven by new physician adoption and insurance coverage in the UK. The company achieved two consecutive quarters of growth for the first time and expects continued quarterly growth. A cost-effectiveness analysis published in a peer-reviewed journal demonstrated Nociscan's superiority over provocative discography, supporting payer coverage. Th...
08-05 10:00
Aclarion, Inc. Adjourns Annual Meeting to Solicit Votes
Aclarion, Inc. ( ($ACON) ) has shared an announcement. On July 7, 2025, Aclario...
07-08 04:51
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Aclarion, Inc. has announced that its Annual Meeting of Stockholders, originally scheduled for July 7, 2025, has been adjourned to July 21, 2025, at 9:30 a.m. Mountain Time, to allow additional time for stockholder voting. The meeting will continue to be held at the Company’s corporate office in Broomfield, Colorado. The record date for stockholder eligibility remains May 9, 2025. Proxies previously submitted will be voted unless revoked, and sto...
07-07 20:01
Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as
07-07 19:33
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
Pliant Therapeutics shares are trading higher. The company announced the voluntary discontinuation of BEACON-IPF.
Pliant Therapeutics shares are trading higher. The company announced the volunt...
06-28 04:20
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
Aclarion, Inc. announced the initiation of the CLARITY trial, enrolling the first patient at the Texas Back Institute. This randomized clinical trial evaluates Nociscan's ability to improve surgical outcomes for chronic low back pain using MR Spectroscopy and AI. Aiming to become the gold standard, Nociscan identifies pain sources non-invasively.中期结果预计在2026年第二季度公布。The trial involves 300 patients across multiple sites, focusing on discogenic low b...
06-25 10:00
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
Dr. Kris Radcliff will present Aclarion's NOCISCAN platform at the State of Spine Surgery Think Tank on June 28, 2025. This platform uses MR Spectroscopy and AI to help identify biomarkers of discogenic pain, aiding in personalized surgical strategies for chronic low back pain. The noninvasive solution is evidence-supported and provides critical insights for optimizing treatment. For more information, visit Aclarion's website or contact them via ...
06-24 11:00
Aclarion John Lorbiecki To Retire As CFO; Company Expects To Appoint New CFO By Q3 2025
https://www.sec.gov/Archives/edgar/data/1635077/000168316825004669/aclarion_8k.htm
06-21 05:14
